Clinical Trial Update: Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling [Phase 1]

View source ↗

Summary

Phase 1 trial of GSK3052230 in combination with chemotherapy or as a single agent in solid tumors with deregulated FGF signaling completed; results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• GSK3052230

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-02-11